

Contents

Contributors

ix

Preface

xiii

1. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment	1
<i>Soma Ghosh, Ilaria Marrocco, and Yosef Yarden</i>	
1. Preface: An introduction to growth factors and the family of receptor tyrosine kinases (RTKs)	2
2. Classification and activation of RTKs	3
3. Oncogenic activation of receptor tyrosine kinases	14
4. Supportive functions of RTKs during tumor progression	18
5. Response and resistance to anti-RTK treatments	23
6. Relevance of RTKs to anti-cancer treatments using immune checkpoint inhibitors	34
7. Perspectives	37
References	38
2. Nuclear receptor tyrosine kinase transport and functions in cancer	59
<i>Mei-Kuang Chen, Jennifer L. Hsu, and Mien-Chie Hung</i>	
1. Introduction	60
2. Nuclear trafficking of RTKs	61
3. The functions of nuclear RTKs in cancer progression and therapeutic resistance	68
4. Conclusion	89
Acknowledgments	90
References	90
3. HER family in cancer progression: From discovery to 2020 and beyond	109
<i>Rakesh Kumar, Bijesh George, Marcia R. Campbell, Nandini Verma, Aswathy Mary Paul, Cecília Melo-Alvim, Leonor Ribeiro, M. Radhakrishna Pillai, Luis Marques da Costa, and Mark M. Moasser</i>	
1. Introduction	110
2. HERs: The big picture	111
3. The HER family: Discoveries, defining moments and historical context	113

4. Dysregulated expression and activity of HERs in cancer	116
5. HER signaling: Off-mechanisms	117
6. Cleaved HERs and therapeutic response	119
7. Ligand-induced HER3 dimerization and signaling	121
8. Function of the inactive HER3 kinase domain	123
9. HER3 localization and trafficking	124
10. HER3 in HER2-amplified cancers	124
11. HER3 in other cancers	126
12. HER3 mutations in cancers	127
13. HER as a prototype for RTK-directed targeted cancer therapy	128
14. Development of HER3 inhibitors	129
15. HER signaling and therapeutic sensitivity	132
16. NRG-HER3 axis: A shared potential effector of acquired drug resistance	133
17. Acquired therapeutic resistance: A model for consideration	136
18. HER-directed therapies: Potential drawbacks and future scope	137
19. Future anticipated advances	142
20. Conclusions	143
Acknowledgments	144
References	144
 4. EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells	 161
Sarmistha Talukdar, Luni Emdad, Swadesh K. Das, and Paul B. Fisher	
1. Introduction	162
2. EGFR and cancer	166
3. Role of EGFR in regulation of cancer stem cells (CSCs)	169
4. Conclusion	180
5. Future prospective	181
References	181
 5. <i>In vivo</i> modeling of the EGFR family in breast cancer progression and therapeutic approaches	 189
Alexandra M. Simond and William J. Muller	
1. Background	190
2. GEMMs representing the Neu/HER2-positive human breast cancer subtype	192
3. Specific recruitment of adaptor proteins to the ErbB2 receptor results in distinct <i>in vivo</i> phenotypes	199
4. ErbB2 tumor development is dependent on activation of the PI3K signaling axis	200
5. EGFR/integrin receptor crosstalk	204

6. ErbB2 signaling in epigenetic regulation and metabolism	208
7. ErbB2 signaling impacts nuclear transcription factors	211
8. Cell cycle regulation in ErbB2-positive breast cancer	212
9. ErbB2 in immune regulation	213
10. Use of mouse models in the development of HER2-targeted therapies	214
References	216
 6. Advances in insulin-like growth factor biology and -directed cancer therapeutics	 229
Lynsey M. Fettig and Douglas Yee	
1. Introduction	230
2. The insulin-like growth factor (IGF) family	230
3. The IGF family in cancer	236
4. Lessons learned and where we go from here	243
5. Conclusions	246
Acknowledgment	247
References	247
 7. MET receptor in oncology: From biomarker to therapeutic target	 259
Raeva Malik, Isa Mambetsariev, Jeremy Fricke, Neal Chawla, Arin Nam, Rebecca Pharaon, and Ravi Salgia	
1. History of MET	260
2. MET genetics	262
3. MET receptor biology	266
4. MET therapeutics	277
5. MET mechanisms of resistance and tumor evolution	282
6. Future directions	286
References	287
 8. Eph receptors as cancer targets for antibody-based therapy	 303
Fenny H.F. Tang, Deodate Davis, Wadih Arap, Renata Pasqualini, and Fernanda I. Staquicini	
1. Receptor tyrosine kinases: Structure and function	304
2. Mechanisms of receptor tyrosine kinases activation	306
3. Receptor tyrosine kinases in human cancers	308
4. Receptor tyrosine kinases as cancer targets	310
5. Conclusion	313
Acknowledgments	314
Conflict of interest	314
References	314

9. RTKs in pathobiology of head and neck cancers 319

Revathy Nadhan, Priya Srinivas, and M. Radhakrishna Pillai

1. Introduction	320
2. Insights into the incidence and etiology of HNC	320
3. Biomarkers for diagnosis and prognosis of HNC	325
4. RTKs as a biomarker for tumorigenesis in HNC	328
5. RTK induced de-differentiation of cancer cells in HNC and its link with stemness	334
6. HPV-RTK link in HNC	335
7. Global miRNAs regulating RTKs in HNC	336
8. Long non-coding RNA (lncRNA) and RTKs in HNC	344
9. TME and RTK activation in HNC	345
10. Autocrine action of growth factors and chemokines on RTKs in HNC	346
11. Tobacco associated carcinogens and RTK activation in HNC	348
12. Targeting RTKs in HNC	349
13. Therapeutic strategies for HPV positive HNC: Emphasis on RTKs	355
14. Drug resistance and RTKs in HNC	356
15. RTK signaling during radiotherapy and immunotherapy	358
16. Can RTK targeting be promising than current therapeutic strategies for HNC?	360
17. Conclusion	361
Acknowledgments	361
References	362

10. Advances in EGFR/HER2-directed clinical research on breast cancer 375

Louis W.C. Chow, Erich F. Lie, and Masakazu Toi

1. Introduction	376
2. Treatment of early HER2-positive breast cancer	378
3. Treatment of advanced HER2-positive breast cancer	391
4. Points of consideration on prognosis and choice of therapies	406
5. Conclusion	419
References	420